Cellebrite DI (NASDAQ:CLBT - Get Free Report) released its quarterly earnings results on Thursday. The company reported $0.12 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.01, RTT News reports. The firm had revenue of $113.28 million for the quarter, compared to analyst estimates of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The company's revenue for the quarter was up 18.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.10 earnings per share. Cellebrite DI updated its Q3 2025 guidance to EPS and its FY 2025 guidance to EPS.
Cellebrite DI Trading Down 2.0%
Shares of CLBT traded down $0.32 during trading hours on Wednesday, hitting $15.48. 1,678,504 shares of the stock traded hands, compared to its average volume of 2,345,980. The business has a fifty day moving average of $14.95 and a 200-day moving average of $17.65. The firm has a market capitalization of $3.71 billion, a PE ratio of -20.37, a price-to-earnings-growth ratio of 3.13 and a beta of 1.27. Cellebrite DI has a 1-year low of $13.10 and a 1-year high of $26.30.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in CLBT. First Trust Advisors LP bought a new stake in Cellebrite DI in the second quarter valued at about $341,000. Alamea Verwaltungs GmbH increased its stake in shares of Cellebrite DI by 31.9% in the 2nd quarter. Alamea Verwaltungs GmbH now owns 22,277 shares of the company's stock valued at $356,000 after acquiring an additional 5,383 shares during the last quarter. SkyView Investment Advisors LLC raised its position in shares of Cellebrite DI by 2.6% in the 2nd quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company's stock valued at $597,000 after acquiring an additional 970 shares during the period. Jane Street Group LLC acquired a new stake in shares of Cellebrite DI in the 2nd quarter valued at approximately $1,272,000. Finally, Tidal Investments LLC boosted its stake in Cellebrite DI by 60.9% during the 2nd quarter. Tidal Investments LLC now owns 96,157 shares of the company's stock worth $1,539,000 after acquiring an additional 36,402 shares during the last quarter. 45.88% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on CLBT shares. Lake Street Capital cut their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a research note on Friday, August 15th. JPMorgan Chase & Co. cut their price objective on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research report on Monday, May 12th. Needham & Company LLC reduced their price objective on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, August 14th. Finally, Wall Street Zen upgraded Cellebrite DI from a "hold" rating to a "buy" rating in a report on Saturday. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $22.40.
View Our Latest Report on CLBT
About Cellebrite DI
(
Get Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Further Reading
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
